A niche vascular-surgery compounder: biologics-led growth, durable pricing power, and a fortress balance sheet create a premium-quality med-tech profile.
Overview
LeMaitre Vascular (LMAT) is a specialized global med-tech company focused on devices, implants, and services for peripheral vascular surgeons, with a differentiated emphasis on open vascular surgery rather than the industry’s dominant endovascular trend. Founded in 1986 and now operating as a diversified multinational with 13 product lines, LMAT sells primarily disposable and implantable products used to treat peripheral vascular disease (PVD), a large and growing global patient pool (~200M) driven by aging populations and chronic comorbidities (diabetes, hypertension). Revenue is overwhelmingly product-based (~95%), supplemented by RestoreFlow human tissue services. The portfolio has shifted decisively toward biologic implants (>50% of revenue), including XenoSure patches, Omniflow II biosynthetic grafts, and Artegraft bovine carotid grafts, valued for infection resistance and clinical handling. The company operates direct sales in 31 countries (152 reps, targeting 165), with sales concentrated in the Americas (64% of Q3 2025), while EMEA (29%) is a key growth vector and APAC (7%) remains longer-term amid regulatory/economic headwinds. Financially, LMAT combines premium margins (Q3 2025 adjusted gross margin 70.8%) with a fortress balance sheet ($343.1M cash/securities, limited debt beyond convertibles), enabling both shareholder returns (14 straight years of dividend growth, $75M buyback authorization) and continued accretive M&A.